Skip to main content

Table 7 Comparative chart of clinical and economic results for treatment of patients with hepatitis C genotype 1

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Therapeutic schedule Total costs LY1 QALY2 Result
Peginterferon-alfa-2a + ribavirin $Brz 31,185 14.51 12.89 peginterferon-alfa-2a is dominant
Peginterferon-alfa-2b + ribavirin $Brz 39,186 14.35 12.50  
  1. Notes: 1LYs – Life years; 2QALYs – Quality Adjusted Life Years.